TITLE

Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis

AUTHOR(S)
Zhenyu Zhou; Chen Chen; Jun Zhang; Xinran Ji; Lifeng Liu; Guichun Zhang; Xuecheng Cao; Pingshan Wang
PUB. DATE
May 2014
SOURCE
International Journal of Clinical & Experimental Pathology;2014, Vol. 7 Issue 5, p2113
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
96450862

 

Related Articles

  • Denosumab: A new injectable treatment for postmenopausal osteoporosis. Whelan, Anne Marie; Raman-Wilms, Lalitha // Canadian Pharmacists Journal;Mar/Apr2011, Vol. 144 Issue 2, p72 

    The article presents a study which determines the efficacy of the injectable denosumab for the treatment of postmenopausal osteoporosis. The researchers have examined the safety and effect of denosumab on bone mineral density (BMD) in the management of postmenopausal osteoporosis. The study...

  • SUBANALYSES AND SUPPLEMENTAL SAFETY OF DENOSUMAB (AMG 162) IN A PHASE 2 STUDY IN POSTMENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY (BMD).  // Osteoporosis International;Mar2006 Supplement 1, Vol. 17, pS60 

    The article presents the abstract of the research "Subanalyses and Supplemental Safety of Denosumab (AMG 162) in a Phase 2 Study in Postmenopausal Women With Low Bone Mineral Density (BMD)."

  • Safety of denosumab reported out to 8 year in extension study. McClung, Michael // Endocrine Today;Oct2011, Vol. 9 Issue 10, p31 

    The article reports on a phase 2 extension study which found that denosumab improved bone mineral density over eight years of treatment for postmenopausal women with low bone mass or osteoporosis.

  • Drug Watch.  // Formulary;Dec2007, Vol. 42 Issue 12, p696 

    The article lists the latest drug development which includes Bazedoxifene for treatment of postmenopausal osteoporosis, Basedoxifene/conjugated estrogens for postmenopausal osteoporosis management and Denosumab for women with low bone mineral in postmenopausal period.

  • Osteoporosis Injection Shows Long-Term Efficacy in Increasing Bone Mineral Density.  // Journal of Gerontological Nursing;Jul2011, Vol. 37 Issue 7, p16 

    The article focuses on long-term data concerning treatment with denosumab into the fourth and fifth year by postmenopausal women with osteoporosis. It states that there were statistically significant, year-over-year increases in total hip and lumbar spine bone mineral density. It mentions that...

  • Yearly and Twice Yearly Pharmacotherapy in Postmenopausal Osteoporosis. Tandon, Vishal R.; Mir, Shakeel Ahmad; Singh, Zorawar; Sharma, Rajesh // JK Science;Jan-Mar2009, Vol. 11 Issue 1, p47 

    The article discusses the importance of yearly and twice yearly pharmacology in treating postmenopausal osteoporosis. It examines the efficacy of Zoledronic acid and Denosumab in treating this osteoporosis. It notes that 5 milligram of intravenous infusion of Zoledronic acid can lower bone...

  • Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis. Scott, Lesley // Drugs & Aging;Jul2014, Vol. 31 Issue 7, p555 

    Subcutaneous denosumab (Prolia [USA, Europe]; Pralia [Japan]) once every 6 months is indicated in several countries for the treatment of postmenopausal women with osteoporosis at increased or high risk for fractures (featured indication). In some countries, it is also indicated for use in...

  • Patients transitioned to denosumab showed gains in BMD. Haigh, Christen; Kalvaitis, Katie // Endocrine Today;10/25/2008, Vol. 6 Issue 19, p8 

    The article discusses a study which revealed gains in bone mineral density among postmenopausal women who transitioned to denosumab.

  • Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Sugimoto, T.; Matsumoto, T.; Hosoi, T.; Miki, T.; Gorai, I.; Yoshikawa, H.; Tanaka, Y.; Tanaka, S.; Fukunaga, M.; Sone, T.; Nakano, T.; Ito, M.; Matsui, S.; Yoneda, T.; Takami, H.; Watanabe, K.; Osakabe, T.; Okubo, N.; Shiraki, M.; Nakamura, T. // Osteoporosis International;Feb2015, Vol. 26 Issue 2, p765 

    Summary: A 12-month extension phase of DIRECT in Japanese subjects with osteoporosis showed that total 3 years of denosumab treatment in Japanese postmenopausal women and men with osteoporosis was associated with low fracture rates, persistent bone turnover marker (BTM) reductions, continuous...

  • Clinical digest. FRACTURE RISK FOLLOWING MENOPAUSE IS REDUCED BY COMBINING MEDICATIONS.  // Nursing Standard;7/31/2013, Vol. 27 Issue 48, p14 

    The article discusses the article "Teriparatide and Denosumab, Alone or Combined, in Women With Postmenopausal Osteoporosis: The DATA Study Randomised Trial" by J. Tsai et al., which was published in the journal "Lancet" and found that osteoporosis medicines increase bone-mineral density and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics